Allergy Thera. Share News (AGY)

Numis reiterates 'buy' on Allergy Therapeutics after full year results

(ShareCast News) - Numis reiterated a 'buy' rating and target price of 37p on Allergy Therapeutics on Monday after the company reported its full year results. Allergy reported a 19% increase in revenue at constant currency to £51.5m in the year ended 30 June as it grew market share in its main Europ

Allergy Therapeutics Expects Revenue Rise Despite Euro Weakening

Allergy Therapeutics sees good results from Acarovac Plus

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics published a one-year follow up study of patients using Acarovac Plus on Friday, in the peer-review journal Immunotherapy. The AIM-traded firm's Acarovac Plus product was described as a microcrystalline tyrosine-adsorbed, house

Allergy Therapeutics Welcomes Positive Follow-Up Results For Acarovac

WINNERS & LOSERS SUMMARY: easyJet And Foxtons In Post-Brexit Warnings

Allergy Therapeutics Sees Delayed US Market Launch For GrassMATAMPL

Allergy Therapeutics Appoints Skyepharma's Wykeman As Finance Director

Allergy Therapeutics Gets Positive Birch Pollen Treatment Results

NetScientic Poaches New Finance Boss From Allergy Therapeutics

Allergy Therapeutics Finance Director Ian Postlethwaite Resigns

BROKER RATINGS SUMMARY: Jefferies Starts Metro Bank With Buy Rating

Allergy Therapeutics Profit Drops On Higher Costs As Revenue Edges Up

Allergy Therapeutics Completes Enrolment For Grass Pollen Drug Study

Allergy Therapeutics Revenue Up In First Half, Full Year Seen In Line

Allergy Therapeutics Begins US Phase II Study Of Grass Allergy Vaccine